Huda Y. Zoghbi - 19 Feb 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/ Huda Y. Zoghbi
Issuer symbol
REGN
Transactions as of
19 Feb 2026
Net transactions value
-$662,794
Form type
4
Filing time
23 Feb 2026, 16:55:58 UTC
Previous filing
06 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zoghbi Huda Y Director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN /s/ Huda Y. Zoghbi 23 Feb 2026 0001681643

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $617,018 +1,638 +96% $376.69 3,341 19 Feb 2026 Direct F1
transaction REGN Common Stock Sale $37,959 -49 -1.5% $774.68 3,292 19 Feb 2026 Direct F1
transaction REGN Common Stock Sale $38,775 -50 -1.5% $775.50 3,242 19 Feb 2026 Direct F1
transaction REGN Common Stock Sale $41,259 -53 -1.6% $778.47 3,189 19 Feb 2026 Direct F1, F2
transaction REGN Common Stock Sale $162,146 -208 -6.5% $779.55 2,981 19 Feb 2026 Direct F1, F3
transaction REGN Common Stock Sale $258,329 -331 -11% $780.45 2,650 19 Feb 2026 Direct F1, F4
transaction REGN Common Stock Sale $163,288 -209 -7.9% $781.28 2,441 19 Feb 2026 Direct F1, F5
transaction REGN Common Stock Sale $233,066 -298 -12% $782.10 2,143 19 Feb 2026 Direct F1, F6
transaction REGN Common Stock Sale $172,324 -220 -10% $783.29 1,923 19 Feb 2026 Direct F1, F7
transaction REGN Common Stock Sale $125,512 -160 -8.3% $784.45 1,763 19 Feb 2026 Direct F1, F8
transaction REGN Common Stock Sale $43,994 -56 -3.2% $785.61 1,707 19 Feb 2026 Direct F1, F9
transaction REGN Common Stock Sale $3,160 -4 -0.23% $790.00 1,703 19 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,638 -67% $0.000000 800 19 Feb 2026 Common Stock 1,638 $376.69 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
F2 Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F3 Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F4 Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F5 Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F6 Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F7 Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F8 Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F9 Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
F10 The stock option vested in three equal annual installments, commencing one year after the date of grant.